Drug maker Aurobindo Pharma today said its consolidated net profit declined 69.08 per cent to Rs 51.50 crore for the first quarter ended June 30, compared to the same period previous fiscal.
Net sales of the company rose to Rs 922.25 crore for the quarter ended June 30, from Rs 852.75 crore in the same period corresponding fiscal, Aurobindo Pharma said in a statement.
The company commenced operations of its formulations facilities in Hyderabad and New Jersey, in the US during the quarter. The company's aggregate investment in these two facilities has been around Rs 475 crore.
"The overheads of these newly operationalised facilities have impacted profitability in the quarter. The company is confident that the commercial benefits of these investments will accrue in the coming quarters," Aurobindo Pharma Chairman Ramprasad Reddy said.
Shares of Aurobindo Pharma today closed at Rs 943.55 on the Bombay Stock Exchange, down 4.04 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app